2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156560
    Z-LVG 119670-31-4 98%
    Z-LVG is an irreversible cysteine proteinase inhibitor. Z-LVG is a tripeptide derivative from cystatin C which can inhibit viral replication. Z-LVG can be used for virus diseases research.
    Z-LVG
  • HY-156578
    DGKα-IN-8 2886717-70-8 98%
    DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC50=22.491 nM; EC50=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection.
    DGKα-IN-8
  • HY-156584
    ODE-Bn-PMEG 1626364-18-8 98%
    ODE-Bn-PMEG is an antiviral compound with strong inhibitory activity against HPV-11, -16, and -18. ODE-Bn-PMEG effectively reduced transient amplification of viral DNA in transfected cells at concentrations well below its cytotoxic levels. ODE-Bn-PMEG showed increased uptake in human foreskin fibroblasts and was able to be efficiently converted to the active antiviral metabolite PMEG diphosphate in vitro. The P-chiral enantiomer of ODE-Bn-PMEG showed comparable antiviral activity, indicating its potential application against multiple HPV types. ODE-Bn-PMEG is a promising candidate for local inhibition of HPV-16, HPV-18, and other high-risk types.
    ODE-Bn-PMEG
  • HY-156599
    Bavtavirine 1956373-71-9 98%
    Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bavtavirine is part of highly active antitiretroviral therapy (HAART) treatment regimen. Bavtavirine can be used for HIV disease research.
    Bavtavirine
  • HY-15662S
    Tulathromycin A-d7 2734920-62-6 98%
    Tulathromycin A-d7 (Tulathromycin-d7) is deuterium labeled Tulathromycin A. Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC50=0.26 μM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects.
    Tulathromycin A-d7
  • HY-156655
    Olgotrelvir 2763596-71-8 98%
    Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells.
    Olgotrelvir
  • HY-156656
    Tirfipiravir 2759996-93-3 98%
    Tirfipiravir is a nucleoside compound and antiviral agent, against the novel coronavirus or influenza virus.
    Tirfipiravir
  • HY-156661
    MurF-IN-1 303790-97-8 98.0%
    MurF-IN-1 (Compound 7) is a MurF inhibitor with an pIC50 of 5.19 against S. pneumoniae MurF.
    MurF-IN-1
  • HY-156665
    HBV-IN-37 380483-01-2 99.04%
    HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM.
    HBV-IN-37
  • HY-156702
    HBV-IN-38 1834483-86-1 98%
    HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections.
    HBV-IN-38
  • HY-156734
    D-4-77 98%
    D-4-77 is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 0.95 μM. D-4-77 has antiviral active with an EC50 value of 0.49 μM. D-4-77 suppresses SARS-CoV-2 Mpro -induced antagonism of the host NF-κB innate immune response.
    D-4-77
  • HY-156892
    SDM25N 342884-62-2
    SDM25N is a Dengue virus (DENV) inhibitor with an EC50 of 1.9 µM. SDM25N inhibits DENV in a cell type-specific manner. SDM25N restricts genomic RNA replication by targeting the viral NS4B protein. SDM25N can be used for DENV infection research.
    SDM25N
  • HY-156959
    Ovalicin 19683-98-8 98%
    Ovalicin is a multi-target inhibitor that targets MetAP2, HRH2, JAK2 and TRPV1, with anti-inflammatory and anti-atopic dermatitis activities. Ovalicin covalently binds to MetAP2 to inhibit its function, thereby blocking the replication of Enterocytozoon bieneusi and Vittaforma corneae. Ovalicin alleviates intestinal injury and prolongs survival in infected mouse models, without showing obvious hepatorenal toxicity. Ovalicin attenuates LPS-induced calcium influx, reduces the infiltration of macrophages and mast cells in the skin, and regulates the expression of inflammation-related genes such as IL-31, effectively relieving allergic symptoms in mouse models. Ovalicin can be used for the research of microsporidiosis and atopic dermatitis.
    Ovalicin
  • HY-156979
    RBT-9 123307-75-5 98%
    RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever.
    RBT-9
  • HY-156980
    Podilfen 13409-53-5 98%
    Podilfen is an active fraction of Delftia strains 2189 with antimicrobial effects.
    Podilfen
  • HY-157015
    Antifungal agent 81 98%
    Antifungal agent 81(G22)exhibitsexcellent in vitro antifungal activities against Valsa mali withIC50values of 0.48 mg/L. Antifungal agent 81also exhibits excellent in vivo protective againstV. maliat 40 mg/L.
    Antifungal agent 81
  • HY-157018
    Antifungal agent 82 98%
    Antifungal agent 82 (compound G34) is a antifungal agent. Antifungal agent 82 exhibits excellent in vitro antifungal activity against Valsa mali, with an EC50 of 0.57 μg/mL. Antifungal agent 82 also exhibits excellent in vivo protective effects against V. mali at 40 μg/mL.
    Antifungal agent 82
  • HY-157021
    SARS-CoV-2-IN-66 1807620-38-7 98%
    SARS-CoV-2-IN-66 (1), a vitaminK derivative, is a SARS-CoV-2 inhibitor, with an EC50 of 70.8 μM in VeroE6/TMPRSS2 cells.
    SARS-CoV-2-IN-66
  • HY-157043
    Antibacterial agent 161 trifluoromethanesulfonate 98%
    Antibacterial agent 161 trifluoromethanesulfonate (Compound 6) has antibacterial activity. Antibacterial agent 161 trifluoromethanesulfonate has high antiproliferative effects against colon cancer and non-small cell lung cancer.
    Antibacterial agent 161 trifluoromethanesulfonate
  • HY-157044
    Antibacterial agent 162 trifluoromethanesulfonate 98%
    Antibacterial agent 162 trifluoromethanesulfonate (compound 7) is an antibacterial agent that exhibits potent inhibitory activity against Staphylococcus aureus, including MRSA. Antibacterial agent 162 trifluoromethanesulfonate is also an anticancer agent and exhibits antiproliferative activity against colon cancer and non-small cell lung cancer cells. Antibacterial agent 162 trifluoromethanesulfonate can be used in anticancer and antibacterial research.
    Antibacterial agent 162 trifluoromethanesulfonate
Cat. No. Product Name / Synonyms Application Reactivity